☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
active ulcerative colitis
Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active U...
October 15, 2021
Janssen Presents Three-Year Data of Stelara (ustekinumab) in P-lll UNIFI LTE Study for the Treatment of Moderately to Severely Act...
July 12, 2021
BMS' Zeposia (ozanimod) Receives the US FDA's Approval for Ulcerative Colitis
May 28, 2021
Takeda's Entyvio (vedolizumab) Receives NMPA's Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease
March 23, 2020
Janssen's Stelara (ustekinumab) Receives the US FDA's Approval for Moderately to Severely Active Ulcerative Colitis
October 21, 2019
Janssen (J&J) Reports Filing of Stelara's (ustekinumab) in Group Type II Variation Application to EMA for Moderately to Severe...
January 9, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.